Histopathological prognostic factors in medulloblastoma: High expression of survivin is related to unfavourable outcome

European Journal of Cancer

Volumn 42, Issue 17, 2006, Pages 2996-3003

  Haberler, C ^a   Slavc, I ^b   Czech, T ^b   Gelpi, E ^a   Heinzl, H ^b   Budka, H ^a   Urban, C ^c   Scarpatetti, M ^c   Ebetsberger Dachs, G ^d   Schindler, C ^d   Jones, N ^e   Klein Franke, A ^f   Maier, H ^g   Jauk, B ^h   Kiefer, A ⁱ   Hainfellner, J A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e Salzburger Landeskliniken   (Austria)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^h GENERAL HOSPITAL KLAGENFURT   (Austria)

ⁱ RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Child; Histopathology; Medulloblastoma; Prognostic markers; Survivin

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; SURVIVIN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUSTRIA; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; CHRONOTHERAPY; CLINICAL PROTOCOL; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAINTENANCE THERAPY; MALE; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; NEWBORN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; MALE; MEDULLOBLASTOMA; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTOR, TRKC; SURVIVAL ANALYSIS;

EID: 33751042197     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.05.038     Document Type: Article

References (36)

1. Radcliffe J., Packer R.J., Atkins T.E., et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 32 (1992) 551-554
2. Zeltzer P.M., Boyett J.M., Finlay J.L., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (1999) 832-845
3. Rickert C.H., and Paulus W. Prognosis-related histomorphological and immunohistochemical markers in central nervous system tumors of childhood and adolescence. Acta Neuropathol (Berl) 109 (2005) 69-92
4. Eberhart C.G., Kepner J.L., Goldthwaite P.T., et al. Histopathologic grading of medulloblastomas: a Paediatric Oncology Group study. Cancer 94 (2002) 552-560
5. Lamont J.M., McManamy C.S., Pearson A.D., Clifford S.C., and Ellison D.W. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10 (2004) 5482-5493
6. McManamy C.S., Lamont J.M., Taylor R.E., et al. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62 (2003) 627-632
7. Gilbertson R., Wickramasinghe C., Hernan R., et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85 (2001) 705-712
8. Grotzer M.A., Janss A.J., Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18 (2000) 1027-1035
9. Fangusaro J.R., Jiang Y., Holloway M.P., et al. Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92 (2005) 359-365
10. Pizem J., Cort A., Zadravec-Zaletel L., and Popovic M. Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol 31 (2005) 422-428
11. Kortmann R.D., Kuhl J., Timmermann B., et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46 (2000) 269-279
12. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352 (2005) 978-986
13. Chang C.H., Housepian E.M., and Herbert Jr. C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93 (1969) 1351-1359
14. Giangaspero F., Bigner S.H., Kleihues P., Pietsch T., and Trojanowski Q.J. Medulloblastoma. In: Kleihues P., and Cavenee W.K. (Eds). World Health Organization classification of tumours. Pathology & genetics: Tumours of the nervous system (2000), IARCPress, Lyon 129-137
15. Giangaspero F., Rigobello L., Badiali M., et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 16 (1992) 687-693
16. Kaplan E.L., and Meier P. Non parametric estimation from incomplete observations. Journal of the American Statistical Association 53 (1985) 457-481
17. Cox D. Regression models and life tables. J Royal Stat Soc B 34 (1972) 187-220
18. Brown H.G., Kepner J.L., Perlman E.J., et al. Large cell/anaplastic medulloblastomas: a Paediatric Oncology Group study. J Neuropathol Exp Neurol 59 (2000) 857-865
19. Leonard J.R., Cai D.X., Rivet D.J., et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 95 (2001) 82-88
20. Ray A., Ho M., Ma J., et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 10 (2004) 7613-7620
21. Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22 (2004) 984-993
22. Giordana M.T., D'Agostino C., Pollo B., et al. Anaplasia is rare and does not influence prognosis in adult medulloblastoma. J Neuropathol Exp Neurol 64 (2005) 869-874
23. Segal R.A., Goumnerova L.C., Kwon Y.K., Stiles C.D., and Pomeroy S.L. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 91 (1994) 12867-12871
24. Eberhart C.G., Kratz J., Wang Y., et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63 (2004) 441-449
25. Korshunov A., Savostikova M., and Ozerov S. Immunohistochemical markers for prognosis of average-risk paediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression. J Neurooncol 58 (2002) 271-279
26. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
27. Herms J.W., Behnke J., Bergmann M., et al. Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 19 (1997) 510-515
28. Korshunov A., Golanov A., Ozerov S., and Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol 16 (1999) 37-44
29. Nam D.H., Wang K.C., Kim Y.M., Chi J.G., Kim S.K., and Cho B.K. The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 15 (2000) 452-456
30. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
31. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
32. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 (2003) 8581-8589
33. Preusser M., Wolfsberger S., Czech T., Slavc I., Budka H., and Hainfellner J.A. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol 124 (2005) 543-549
34. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., and Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133 (1984) 1710-1715
35. Chakravarti A., Zhai G.G., Zhang M., et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23 (2004) 7494-7506
36. Rodel F., Hoffmann J., Distel L., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65 (2005) 4881-4887